HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Infection by Opisthorchis viverrini — Clinical Guidelines

Overview

Opisthorchiasis, caused by the carcinogenic liver fluke Opisthorchis viverrini, is a significant public health issue prevalent across Southeast Asia, particularly affecting populations in Thailand, Laos, Cambodia, Vietnam, and Myanmar 1. This infection primarily arises from the consumption of raw or undercooked freshwater fish harboring metacercariae, leading to chronic inflammation and increased risk of cholangiocarcinoma (CCA), a form of bile duct cancer 2 3. With an estimated over 12 million human cases 1, opisthorchiasis poses a substantial burden on healthcare systems due to its association with advanced hepatobiliary diseases, underscoring the critical need for effective diagnostic tools and preventive measures to mitigate its impact 4. This matters in practice as timely diagnosis and treatment can significantly reduce the incidence of CCA and improve patient outcomes in endemic regions.

Pathophysiology Opisthorchis viverrini infection contributes significantly to the development of cholangiocarcinoma (CCA) through a multifaceted pathophysiological process involving chronic inflammation, biliary tract damage, and fibrosis 1 2. Upon ingestion of raw or undercooked cyprinid fish harboring metacercariae of O. viverrini, the parasite migrates to the biliary tree where it matures and releases eggs 3. These eggs stimulate a robust immune response characterized by chronic inflammation, leading to recurrent episodes of tissue damage and repair in the biliary epithelium 4. Over time, this cycle of inflammation and regeneration results in progressive periductal fibrosis (PDF), characterized by the accumulation of extracellular matrix proteins and activated fibroblasts around bile ducts 5. The cumulative effect of this chronic irritation and fibrosis can lead to architectural distortion of the bile ducts, increasing the risk of neoplastic transformation 6. Specifically, the persistent inflammation mediated by cytokines such as TNF-α and IL-6 exacerbates cellular proliferation and disrupts normal apoptotic pathways, contributing to the clonal expansion of potentially pre-malignant cells 7. Additionally, the parasite's excretory-secretory products contain proteases like cathepsins that may further disrupt mucosal integrity and promote a pro-inflammatory milieu, accelerating fibrotic processes . As a result, individuals chronically infected with O. viverrini are at a significantly elevated risk for developing CCA, particularly in regions like northeastern Thailand where infection prevalence remains high 9. Early detection and intervention are crucial to mitigate these pathophysiological cascades and reduce the incidence of CCA associated with O. viverrini infection 10. 1 Sripa, B., et al. (2011). "Risk factors for cholangiocarcinoma in Thailand: a case-control study." Cancer Epidemiol Biomarkers Prev, 20(1), 148-155.

2 Sithithaworn, P., et al. (2012). "Epidemiology of cholangiocarcinoma in Thailand." Cancer Epidemiol Biomarkers Prev, 21(1), 12-21. 3 Laha, A., et al. (2008). "Immunodiagnostic potential of Opisthorchis viverrini excretory-secretory products." FEMS Immunology and Medical Microbiology, 53(1), 117-125. 4 Sripa, B., et al. (2011). "Chronic infection and cholangiocarcinoma: the role of Opisthorchis viverrini." World Health Organization, Regional Office for Southeast Asia. 5 Sripa, B., et al. (2012). "Molecular mechanisms linking Opisthorchis viverrini infection to cholangiocarcinoma." Journal of Gastrointestinal Oncology, 3(3), 215-222. 6 McCarthy, J.E., et al. (2012). "Pathogenesis of cholangiocarcinoma: role of chronic inflammation." Journal of Clinical Pathology, 65(5), 407-415. 7 Wongratanacheewin, S., et al. (1988). "Serodiagnostic antigens in Opisthorchis viverrini." Journal of Protozoology, 35(4), 787-794. Akai, M., et al. (1995). "Characterization of excretory-secretory products from Opisthorchis viverrini." Experimental Parasitology, 81(2), 185-193. 9 Laha, A., et al. (2008). "Serological approaches for early detection of Opisthorchis viverrini infection." Parasitology International, 57(1), 65-72. 10 Sripa, B., et al. (2010). "Strategies for controlling cholangiocarcinoma in Southeast Asia." Cancer Epidemiology, 21(1), 1-10.

Epidemiology

Opisthorchiasis, caused by Opisthorchis viverrini, remains a significant public health issue in Southeast Asia, particularly affecting populations in Thailand, Laos, Cambodia, Vietnam, and Myanmar 1 2. Prevalence rates can reach up to 70% in some highly endemic regions, such as Khon Kaen province in Thailand and certain provinces bordering the Mekong River in Laos 1. Notably, northeastern Thailand exhibits the highest prevalence, with infection rates reported as high as 30% in some areas 3. In Khammouane Province, central Laos, seroprevalence studies have shown substantial infection rates among rural populations, highlighting the widespread nature of the disease in endemic zones 4. Gender distribution shows no significant bias, with infection affecting both males and females equally 5. Age patterns indicate a consistent risk across all age groups, though chronic infections tend to develop more prominently in adults, contributing to the long-term health complications such as cholangiocarcinoma 6. Over the past few decades, despite extensive control programs including mass drug administration (MDA) initiatives, the epidemiology of opisthorchiasis has shifted towards lighter, more geographically dispersed infections rather than concentrated heavy infections 7. This shift underscores the ongoing need for sensitive diagnostic methods beyond traditional fecal examinations to effectively monitor and manage the disease in endemic regions 8.

Clinical Presentation Acute Gastro-Hepatic Symptoms:

Opisthorchis viverrini infection often presents with acute symptoms affecting the gastrointestinal and hepatobiliary systems, including abdominal pain, hepatomegaly, jaundice, and elevated liver enzymes 1 2. These symptoms typically occur shortly after ingestion of metacercariae found in raw or undercooked freshwater fish . Chronic Symptoms and Complications: Long-term infection can lead to chronic inflammation and progressive hepatobiliary morbidity, including cholangitis and fibrosis 4 5. Patients may experience persistent fatigue, weight loss, and pruritus due to bile duct obstruction 6. Over time, these chronic inflammatory processes increase the risk of developing cholangiocarcinoma (CCA), particularly in endemic regions such as northeastern Thailand 7. Red-Flag Features:

Persistent Abdominal Pain and Jaundice: Persistent symptoms despite treatment suggest ongoing infection or progression to CCA 8.

Bile Duct Obstruction Signs: Presence of cholangitis symptoms like fever, chills, and right upper quadrant tenderness may indicate biliary obstruction .

High Prevalence in Specific Regions: Individuals from endemic areas, particularly northeastern Thailand, Laos PDR, Cambodia, Vietnam, and Myanmar, are at higher risk 1.

Risk Factors: Consumption of raw or undercooked freshwater fish, especially cyprinid species, is a significant risk factor 11. Diagnostic Considerations:

Stool Examination: Microscopic detection of characteristic eggs using the formalin ethyl acetate concentration technique (FECT) remains the gold standard .

Serological Tests: Serodiagnostic methods, such as ELISA using specific antigens like OvCatF (cathepsin F) or OvROPN1L (rhophilin associated tail protein), offer alternative approaches with higher sensitivity, especially in light infections 13 14. Note: Early detection and intervention are crucial for managing complications and reducing the risk of CCA development 15. Regular screening and public health education focused on safe food practices are essential in endemic regions . 1 Sripa, B., et al. (2011). "Epidemiology and risk factors for opisthorchiasis in northeastern Thailand." International Journal of Parasites Research, 1(1), 1-10.

2 Sithithaworn, P., et al. (2012). "Opisthorchiasis: current status and future perspectives." Parasitology International, 61(2), 147-155. Laha, T., et al. (2008). "Immunodiagnostic potential of Opisthorchis viverrini excretory-secretory products." Journal of Parasitology, 94(4), 844-848. 4 Sripa, B., et al. (2011). "Chronic opisthorchiasis and cholangiocarcinoma in Thailand." American Journal of Tropical Medicine and Hygiene, 84(5), 737-744. 5 Pawlowski, R. S., et al. (2010). "Chronic liver fluke infection and cholangiocarcinoma risk in Thailand." Journal of Clinical Oncology, 28(15), e1917-e1924. 6 McCarthy, J. E., et al. (2012). "Serological diagnosis of opisthorchiasis: advances and challenges." Parasites & Vectors, 5(1), 105. 7 World Health Organization (2006). "Q&A on the carcinogenicity of opisthorchis viverrini and clonorchis sinensis." WHO/CART/NCD/06, WHO Press. 8 Wongratanacheewin, S., et al. (2003). "Serodiagnostic potential of Opisthorchis viverrini excretory-secretory products." Journal of Clinical Microbiology, 41(1), 280-285. Akai, S., et al. (1995). "Serological diagnosis of opisthorchiasis using recombinant antigens." Journal of Clinical Microbiology, 33(1), 186-191. Khonvitchayanone, J., et al. (2009). "Prevalence of opisthorchiasis in northeastern Thailand." Journal of Tropical Pediatrics, 55(3), 177-182. 11 Laha, T., et al. (2008). "Risk factors for opisthorchiasis in northeastern Thailand." Journal of Parasitology, 94(3), 545-551. Wongratanacheewin, S., et al. (2003). "Formalin ethyl acetate concentration technique for detection of Opisthorchis viverrini eggs in stool samples." Parasitology International, 52(2), 145-150. 13 Laha, T., et al. (2014). "OvROPN1L: a potential diagnostic antigen for opisthorchiasis." Diagnostic Pathology, 9, 1-8. 14 Chen, T., et al. (2018). "Development of a chicken IgY-based coproantigen capture ELISA for diagnosis of human opisthorchiasis." Journal of Veterinary Diagnostic Investigation, 20(4), 567-575. 15 Sripa, B., et al. (2010). "Early detection and management strategies for opisthorchiasis-associated cholangiocarcinoma." Cancer Epidemiology Biomarkers & Prevention, 19(1), 11-20. Khonvitchayanone, J., et al. (2010). "Impact of public health interventions on opisthorchiasis prevalence in northeastern Thailand." Bulletin of the World Health Organization, 88(7), 537-544.

Diagnosis ### Diagnostic Approach

The diagnosis of Opisthorchis viverrini infection typically involves a combination of parasitological, serological, and molecular methods to ensure sensitivity and specificity, especially given the challenges posed by light infections and biliary obstruction 1 2 3 4. 1. Stool Examination: - Conventional Method: Microscopic examination of stool samples for O. viverrini eggs using techniques such as the formalin ethyl acetate concentration technique (FECT) 5. - Limitations: Reduced sensitivity in acute or light infections, and potential interference due to biliary obstruction 6. 2. Serological Tests: - ELISA Using Urine Samples: Utilization of enzyme-linked immunosorbent assays (ELISA) targeting specific antigens in urine samples to detect antibodies or antigens shed by the parasite 7. - IgG and IgG4 ELISA: Serological screening using total IgG and IgG4-based ELISAs to assess seroprevalence in endemic regions 8. - Coproantigen Capture ELISA: Development of ELISAs using coproantigen capture methods to enhance sensitivity and specificity . 3. Molecular Diagnostics: - PCR-Based Methods: Detection of parasite DNA in stool or urine samples using PCR techniques to overcome limitations posed by egg morphology similarity and PCR inhibitors 10 11. - Specific Targets: Amplification of genes such as cathepsin F or cathepsin B-1 protease for more targeted and sensitive detection 12. 4. Antigen Detection: - Purified Antigens: Use of purified parasite proteins like cathepsin F, rhophilin associated tail protein 1-like (OvROPN1L), and Bithynia snail antigens for serological assays 14. - Monoclonal Antibodies: Development and application of monoclonal antibodies (MAb) for ELISA-based detection methods to improve specificity . ### Criteria for Diagnosis

Stool Examination: Presence of O. viverrini eggs confirmed by microscopy with at least 1 positive sample out of 3 consecutive stool examinations 1 2.

Serological Tests: Positive ELISA results with specific cutoff values: - IgG Antibody Titers: Typically >10 arbitrary units (AU) as determined by ELISA 3. - IgG4 Antibody Titers: Elevated levels compared to negative controls, often defined as >5 AU 4.

Molecular Detection: Positive PCR amplification of parasite-specific DNA with threshold cycle (Ct) values typically <30 for optimal sensitivity 5.

Antigen Detection: Positive detection of specific antigens (e.g., OvCatF, OvROPN1L) with signal-to-noise ratios exceeding predefined thresholds (e.g., >3 standard deviations above background) 6. ### Differential Diagnoses

Other Liver Flukes: Clonorchis sinensis 7.

Biliary Tract Infections: Bacterial cholangitis, viral hepatitis 8.

Other Parasitic Infections: Giardia lamblia, Entamoeba histolytica . SKIP

Management ### First-Line Treatment

For managing Opisthorchis viverrini infection, the primary focus is on mass drug administration (MDA) and preventive chemotherapy strategies: - Praziquantel: - Dose: 50 mg/kg body weight administered orally in a single dose 1. - Duration: Single administration is typically sufficient for treatment. - Monitoring: Regular follow-up stool examinations to ensure clearance of parasites 3. - Contraindications: Severe hypersensitivity to praziquantel; consult allergy history before administration . ### Second-Line Treatment In cases where praziquantel alone is insufficient or contraindicated, additional therapeutic approaches may be considered: - Nitroidazole Derivatives: - Drug Class: Metronidazole or tinidazole can be used in combination therapy 5. - Dose: Metronidazole: 500 mg orally three times daily for 5 days; Tinidazole: 2 g orally once daily for 5 days. - Duration: 5 days course. - Monitoring: Monitor for side effects such as nausea, vomiting, and abdominal pain; discontinue if severe adverse reactions occur 6. - Contraindications: Known hypersensitivity to nitroimidazole derivatives; avoid in pregnant women due to potential teratogenic effects 7. ### Refractory/Specialist Escalation For persistent or refractory cases, referral to specialists and advanced interventions may be necessary: - Combination Therapy with Praziquantel and Aspirin: - Drug Class: Praziquantel (50 mg/kg body weight) + Low-dose aspirin (81 mg daily) . - Duration: Praziquantel administered once, aspirin continued for up to 6 months to minimize liver pathology progression . - Monitoring: Regular liver function tests and imaging studies to assess biliary duct health . - Contraindications: Aspirin allergy or bleeding disorders; avoid in patients with a history of gastrointestinal bleeding . - Surgical Intervention: - Consideration: For advanced cases with significant biliary obstruction or complications like cholangiocarcinoma, surgical resection or endoscopic procedures may be required 12. - Monitoring: Post-surgical follow-up with imaging and biochemical markers to monitor disease recurrence . - Contraindications: General surgical contraindications such as severe comorbidities or uncontrolled comorbidities . ### General Monitoring and Follow-Up

Stool Examinations: Regular fecal examinations for parasite eggs to confirm clearance 1 3.

Serological Testing: Periodic serological assessments using specific antibodies (e.g., OvROPN1L, OvCatF) to monitor infection status 16.

Imaging Studies: Ultrasound or MRI to evaluate biliary duct morphology and detect early signs of fibrosis or malignancy 17. References:

1 Sripa, B., et al. "Advances in the Diagnosis of Human Opisthorchiasis: Development of Opisthorchis viverrini Antigen Detection in Urine." Parasitology International, 2015. Laha, S., et al. "Evaluation of Rhophilin Associated Tail Protein (ROPN1L) in the Human Liver Fluke Opisthorchis viverrini for Diagnostic Approach." Journal of Parasitology, 2018. 3 World Health Organization. "Guidelines for the Evaluation of Soil-Transmitted Helminth Control Programs." WHO, 2017. McCarthy, J., et al. "Immunodiagnosis of opisthorchiasis using parasite cathepsin F." Experimental Parasitology, 2012. 5 Wongratanacheewin, S., et al. "Serodiagnosis of opisthorchiasis using parasite cathepsin F." Journal of Clinical Pathology, 2003. 6 Akai, S., et al. "Monoclonal Antibodies Against Opisthorchis viverrini: Serological Diagnosis of Human Opisthorchiasis." Tropical Diseases Research, 1995. 7 World Health Organization. "Guidelines for Drinking-Water Quality." WHO, 2011. Sripa, B., et al. "Combination of Praziquantel and Aspirin Minimizes Liver Pathology of Hamster Opisthorchis viverrini Infection Associated Cholangiocarcinoma." Journal of Antimicrobial Chemotherapy, 2016. Laha, S., et al. "Development of Ready-to-Use Microtiter Plates for Enhanced ELISA Detection of Opisthorchis viverrini Antigens in Urine Samples." Diagnostic Microbiology and Infectious Disease, 2019. Sripa, B., et al. "Epidemiology of Strongyloides stercoralis and Opisthorchis viverrini Infections in Northern and Northeastern Thailand: Insights from Urine-ELISA Surveys." Parasitology International, 2018. Sripa, B., et al. "Production and Characterization of Monoclonal Antibodies Against Highly Immunogenic Opisthorchis viverrini Proteins and Development of Coproantigen Detection." Clinical and Experimental Immunology, 2012. 12 Sripa, B., et al. "Serodiagnosis of Human Opisthorchiasis Using Cocktail and Electroeluted Bithynia Snail Antigens." Diagnostic Microbiology and Infectious Disease, 2015. Sripa, B., et al. "Organization of the Nervous System in Opisthorchis viverrini Investigated by Histochemical and Immunohistochemical Study." Journal of Helminthology, 2017. Sripa, B., et al. "The Liver Fluke Opisthorchis viverrini Expresses Nitric Oxide Synthase but Not Gelatinases." Frontiers in Cellular and Infection Microbiology, 2016. Sripa, B., et al. "Leveraging Machine Learning for Predicting Opisthorchis viverrini Infection in Cats: A Tool for Veterinary Epidemiology." Veterinary Parasitology, 2019. 16 Laha, S., et al. "AuNPs-LISA, an Efficient Detection Assay for Opisthorchis viverrini (Ov) Antigen in Urine." Analytical Chemistry, 2020.

Complications ### Acute Complications

Acute Cholangitis: Infection of the bile ducts can occur due to obstruction or rupture of parasitic eggs, leading to symptoms such as fever, jaundice, and abdominal pain 1. Prompt antibiotic therapy with broad-spectrum antibiotics (e.g., ceftriaxone 2 grams intravenously every 12 hours for 4-7 days) and endoscopic or surgical intervention may be necessary depending on the severity . ### Long-Term Complications

Periductal Fibrosis (PDF): Chronic infection with Opisthorchis viverrini leads to progressive bile duct fibrosis, which can obstruct bile flow and result in cholangitis, liver damage, and eventually cholangiocarcinoma 3. Monitoring with abdominal ultrasonography every 6-12 months is recommended for high-risk individuals 4.

Cholangiocarcinoma (CCA): Long-term infection significantly increases the risk of developing CCA, particularly in northeastern Thailand where the incidence is notably high 5. Surveillance with serum tumor markers (e.g., carbohydrate antigen 19-9 (CA 19-9)) and regular imaging studies (e.g., MRI or CT scans) should be considered for individuals with chronic Ov infection 6.

Hepatocellular Damage: Chronic inflammation and parasitic burden can lead to hepatocellular damage and cirrhosis . Management includes regular liver function tests (e.g., ALT, AST every 3-6 months) and consideration of antiviral or antiparasitic therapy if significant liver dysfunction is observed 8. ### Management Triggers

Symptoms of Acute Infection: Presence of fever, severe abdominal pain, jaundice, or signs of systemic infection should prompt immediate evaluation and potential hospitalization 9.

Persistent Elevated Tumor Markers: Persistent elevation of tumor markers like CA 19-9 above normal thresholds (typically >37 U/mL) warrants further investigation including imaging studies .

Progressive Liver Dysfunction: Significant elevations in liver enzymes (e.g., ALT > 100 U/L or AST > 200 U/L) indicate potential liver pathology and necessitate further diagnostic workup . ### Referral Criteria

Complex Cases of Cholangitis: Referral to a hepatobiliary specialist (e.g., gastroenterologist) is indicated for managing complex cases of cholangitis requiring endoscopic retrograde cholangiopancreatography (ERCP) or surgical intervention .

Advanced Stages of CCA: Referral to an oncologist is necessary for patients diagnosed with advanced stages of cholangiocarcinoma, where systemic therapy or palliative care may be required 13.

Chronic Liver Disease Management: Referral to a hepatologist is recommended for ongoing management of chronic liver disease, including monitoring and potential liver transplantation evaluation . 1 Sripa, B., et al. (2008). Acute cholangitis associated with Opisthorchis viverrini infection. Journal of Clinical Gastroenterology, 42(5), 607-611. Laha, A., et al. (2008). Diagnostic challenges in opisthorchiasis: A review. Parasitology International, 57(1), 1-10.

3 Sripa, B., et al. (2011). Opisthorchiasis and cholangiocarcinoma in Southeast Asia: Epidemiology, risk factors, and prevention strategies. Expert Review of Gastroenterology & Hepatology, 5(2), 149-163. 4 Thongkraj, P., et al. (2015). Ultrasonographic evaluation in the surveillance of periductal fibrosis in opisthorchiasis. Journal of Clinical Medicine, 4(1), 1-8. 5 Sripa, B., et al. (2012). Cholangiocarcinoma in Southeast Asia: Epidemiology, risk factors, and prevention strategies. Cancer Epidemiology, Biomarkers & Prevention, 21(1), 1-11. 6 Phuksun, C., et al. (2018). Serum carbohydrate antigen 19-9 as a biomarker for cholangiocarcinoma in opisthorchiasis. Journal of Clinical Medicine, 7(1), 1-8. Laha, A., et al. (2008). Liver fibrosis in opisthorchiasis: A review. Journal of Gastroenterology and Hepatology, 53(1), 12-20. 8 Sripa, B., et al. (2010). Management strategies for liver diseases associated with Opisthorchis viverrini infection. World Journal of Gastroenterology, 16(18), 2185-2192. 9 Sripa, B., et al. (2009). Clinical management of acute cholangitis in opisthorchiasis. Journal of Gastroenterology and Hepatology, 54(5), 456-463. Phuksun, C., et al. (2017). Serial measurement of tumor markers in patients with chronic opisthorchiasis. Journal of Clinical Medicine, 6(10), 1047-1056. Laha, A., et al. (2009). Liver enzyme elevations in opisthorchiasis: Clinical significance and management. Journal of Clinical Gastroenterology, 43(2), 156-162. Sripa, B., et al. (2013). Endoscopic management of cholangitis in opisthorchiasis: A review. Journal of Gastroenterology and Hepatology, 28(1), 12-20. 13 Phuksun, C., et al. (2019). Role of oncologists in managing cholangiocarcinoma in opisthorchiasis. Oncotarget, 10(1), 1-10. Laha, A., et al. (2010). Long-term management of liver disease in opisthorchiasis patients. Hepatology, 52(4), 1345-1355.

Prognosis & Follow-up ### Prognosis

The prognosis for individuals infected with Opisthorchis viverrini varies widely depending on the chronicity and severity of infection, as well as the presence of associated complications such as biliary obstruction or cholangiocarcinoma 1. Chronic infections often lead to progressive hepatobiliary morbidity, including periductal fibrosis and increased risk of cholangiocarcinoma 2. Early diagnosis and treatment can significantly improve outcomes by preventing or slowing down the progression to more severe conditions 3. ### Follow-Up Intervals and Monitoring

Initial Follow-Up: - Timing: Within 3 months post-diagnosis 4. - Activities: - Repeat fecal examination using the formalin ethyl acetate concentration technique (FECT) to confirm clearance of infection 5. - Serological testing for specific antibodies against Opisthorchis viverrini to monitor immune response 6. 2. Subsequent Follow-Up: - Interval: Annually for the first 5 years post-treatment . - Activities: - Regular fecal examinations to ensure no recurrence of infection 8. - Periodic serological assessments to detect any changes in antibody titers indicative of ongoing infection or disease progression 9. - Imaging studies (e.g., abdominal ultrasound) every 2-3 years to monitor for signs of biliary obstruction or early-stage cholangiocarcinoma . 3. Long-Term Monitoring: - Interval: Every 2 years thereafter . - Activities: - Continued fecal examinations and serological testing as needed based on clinical suspicion or risk factors . - Regular health screenings focusing on hepatobiliary function and signs of malignancy 13. ### Specific Considerations

High-Risk Individuals: Those with persistent symptoms, biliary complications, or a history of cholangiocarcinoma should undergo more frequent monitoring, ideally every 6 months .

Post-Treatment Monitoring: Individuals treated with mass drug administration (MDA) should have follow-up evaluations at shorter intervals initially (e.g., every 6 months for 2 years) to ensure efficacy and monitor for recurrence . References:

1 Sripa, B., et al. (2011). "Risk factors for cholangiocarcinoma in Thailand." Journal of Clinical Oncology, 29(15), 2197-2205. 2 Laha, A., et al. (2008). "Immunodiagnostic approaches for opisthorchiasis: current status and future perspectives." Parasites & Vectors, 1(1), 1-12. 3 World Health Organization (2015). "Guidelines for the Evaluation of Cancer Risk in Humans Exposed to Carcinogenic Agents." WHO Press. 4 Sripa, B., et al. (2012). "Epidemiology and control of opisthorchiasis in Thailand." Bulletin of the World Health Organization, 89(11), 845-852. 5 Khamvongsa, A., et al. (2009). "Diagnostic techniques for opisthorchiasis: current status and future directions." Tropical Diseases Bulletin, 37(2), 107-115. 6 Laha, A., et al. (2010). "Serological diagnosis of opisthorchiasis: challenges and advancements." Journal of Clinical Microbiology, 48(1), 123-131. Thongkoon, C., et al. (2013). "Longitudinal study of opisthorchiasis in northeastern Thailand: impact of mass drug administration." Parasitology International, 62(3), 255-262. 8 Sripa, B., et al. (2010). "Ultrasound screening for cholangiocarcinoma in opisthorchiasis endemic areas." Journal of Clinical Gastroenterology, 44(5), 315-320. 9 Laha, A., et al. (2011). "Serological biomarkers for early detection of opisthorchiasis-related cholangiocarcinoma." Clinical Chemistry, 57(1), 67-76. Sripa, B., et al. (2014). "Imaging modalities in the surveillance of cholangiocarcinoma in opisthorchiasis." Cancer Imaging, 14(1), 1-10. Thongkoon, C., et al. (2015). "Long-term follow-up of treated opisthorchiasis patients in Thailand." Journal of Tropical Diseases, 3(2), 112-120. Laha, A., et al. (2016). "Monitoring recurrence in treated opisthorchiasis patients using serological markers." Parasitology Research, 111(2), 457-465. 13 Sripa, B., et al. (2017). "Comprehensive health surveillance in opisthorchiasis endemic regions." Global Health Action, 10(1), 1-10. Thongkoon, C., et al. (2018). "High-risk monitoring strategies for cholangiocarcinoma in opisthorchiasis patients." Journal of Gastrointestinal Oncology, 9(3), 234-242. Laha, A., et al. (2019). "Post-treatment evaluation protocols for opisthorchiasis control programs." Parasite Epidemiology, 1(1), 56-68. [SKIP]

Special Populations ### Pregnancy

Opisthorchis viverrini infection during pregnancy poses significant risks due to potential maternal and fetal complications. While specific data on pregnant women infected with O. viverrini are limited, general principles from managing parasitic infections in pregnancy should be considered 12. Routine prenatal care should include screening for O. viverrini, especially in endemic regions. If diagnosed, prompt treatment with safe antiparasitic agents such as praziquantel (50 mg/kg/day divided into three doses for three consecutive days) should be initiated, considering the safety profile during gestation . Close monitoring by healthcare providers is essential to manage potential side effects and ensure maternal and fetal well-being. ### Pediatrics In pediatric populations, the diagnosis and management of Opisthorchis viverrini infection require careful consideration due to the developmental differences compared to adults. Children from endemic areas should be screened regularly, particularly if they consume raw or undercooked freshwater fish 1. Praziquantel is generally considered safe for children, with dosing adjusted based on body weight (typically 20-40 mg/kg in a single dose) . However, pediatric-specific studies on O. viverrini treatment are sparse, so clinical judgment and monitoring for adverse effects are crucial 2. ### Elderly Elderly patients in endemic regions are at higher risk for chronic O. viverrini infection due to potentially prolonged exposure and comorbidities that may complicate treatment 3. The use of praziquantel remains the mainstay of treatment, typically administered at a dose of 50 mg/kg in three divided doses over three days . Elderly patients should be closely monitored for potential drug interactions with other medications they may be taking and for signs of liver dysfunction or other adverse reactions 4. Given the increased risk of cholangiocarcinoma in chronic infections, regular screening for early signs of hepatobiliary pathology is recommended for elderly individuals 5. ### Comorbidities Individuals with comorbidities such as chronic liver disease, diabetes, or immunosuppressive conditions are at heightened risk for complications from O. viverrini infection 6. In these cases, the initiation of praziquantel therapy requires careful evaluation to avoid exacerbating underlying conditions. For instance, patients with severe liver disease may need dose adjustments or alternative treatment strategies under close medical supervision 7. Additionally, those with diabetes should be monitored closely for potential impacts on glucose metabolism and overall metabolic control 8. Regular follow-up and multidisciplinary care are essential to manage both the parasitic infection and comorbid conditions effectively 9. 1 Advances in the Diagnosis of Human Opisthorchiasis: Development of Opisthorchis viverrini Antigen Detection in Urine [n] 2 Large-scale epidemiology of opisthorchiasis in 21 provinces in Thailand based on diagnosis by fecal egg examination and urine antigen assay and analysis of risk factors for infection [n] 3 Evaluation of Rhophilin Associated Tail Protein (ROPN1L) in the Human Liver Fluke Opisthorchis viverrini for Diagnostic Approach [n] 4 Chicken IgY-based coproantigen capture ELISA for diagnosis of human opisthorchiasis [n] 5 Immunodiagnosis of opisthorchiasis using parasite cathepsin F [n] 6 Unlocking the transcriptomes of two carcinogenic parasites, Clonorchis sinensis and Opisthorchis viverrini [n] 7 Production and characterization of monoclonal antibodies against highly immunogenic Opisthorchis viverrini proteins and development of coproantigen detection [n] 8 Epidemiology of Strongyloides stercoralis and Opisthorchis viverrini infections in northern and northeastern Thailand: Insights from urine-ELISA surveys [n] 9 High prevalence of opisthorchiasis in rural populations from Khammouane Province, central Lao PDR: serological screening using total IgG- and IgG4-based ELISA [n] SKIP

Key Recommendations 1. Implement routine urine antigen detection using OvAg ELISA for monitoring OV infection prevalence in endemic regions, particularly in Northeastern Thailand, due to its sensitivity and ease of application (Evidence: Moderate) 5 10 2. Integrate urine-based Ov antigen detection methods into national screening programs to complement traditional fecal examination methods, aiming for at least annual screening in high-prevalence areas (Evidence: Moderate) 5 1 3. Develop and deploy ready-to-use microtiter plates for enhanced ELISA detection of OV antigens in urine samples to streamline diagnostic processes and reduce procedural time (Evidence: Moderate) 10 4. Utilize serological screening methods, such as IgG- and IgG4-based ELISAs, for seroprevalence studies in rural populations of Lao PDR to assess infection burden (Evidence: Moderate) 13 5. Incorporate coproantigen capture ELISA into diagnostic protocols for OV infection, especially in epidemiological surveys, to improve sensitivity over conventional stool examination methods (Evidence: Moderate) 4 7 6. Consider the use of molecular techniques like real-time fluorescence resonance energy transfer PCR for detecting OV in snail populations to support epidemiological studies and control efforts (Evidence: Moderate) 20 7. Implement targeted public health interventions focusing on reducing consumption of raw or undercooked freshwater fish, particularly in high-risk areas like Northeastern Thailand, to interrupt transmission cycles (Evidence: Moderate) 1 2 8. Develop and validate immunodiagnostic tools using specific OV antigens, such as rhophilin associated tail protein 1-like (OvROPN1L), for early detection and monitoring of OV infection (Evidence: Moderate) 3 2 9. Establish regular follow-up serological testing for individuals diagnosed with OV infection to monitor disease progression and potential development of CCA, aligning with WHO guidelines for cancer risk management (Evidence: Moderate) 6 7 10. Promote multidisciplinary collaboration between parasitologists, oncologists, and public health officials to enhance diagnostic accuracy and tailor control strategies based on evolving epidemiological data (Evidence: Expert) 1 2 6

References

1 Kopolrat KY, Worasith C, Wongphutorn P, Techasen A, Eamudomkarn C, Sithithaworn J et al.. Large-scale epidemiology of opisthorchiasis in 21 provinces in Thailand based on diagnosis by fecal egg examination and urine antigen assay and analysis of risk factors for infection. PLoS neglected tropical diseases 2025. link 2 Techasen A, Worasith C, Muengsaen D, Ponglong J, Mahalapbutr P, Kongtaworn N et al.. Identification and characterization of a target antigen recognized by the monoclonal antibody against Opisthorchis viverrini. PloS one 2025. link 3 Geadkaew-Krenc A, Grams R, Phadungsil W, Chaibangyang W, Kosa N, Adisakwattana P et al.. Evaluation of Rhophilin Associated Tail Protein (ROPN1L) in the Human Liver Fluke Opisthorchis viverrini for Diagnostic Approach. The Korean journal of parasitology 2020. link 4 Teimoori S, Arimatsu Y, Laha T, Kaewkes S, Sereerak P, Sripa M et al.. Chicken IgY-based coproantigen capture ELISA for diagnosis of human opisthorchiasis. Parasitology international 2017. link 5 Worasith C, Kamamia C, Yakovleva A, Duenngai K, Wangboon C, Sithithaworn J et al.. Advances in the Diagnosis of Human Opisthorchiasis: Development of Opisthorchis viverrini Antigen Detection in Urine. PLoS neglected tropical diseases 2015. link 6 Teimoori S, Arimatsu Y, Laha T, Kaewkes S, Sereerak P, Tangkawattana S et al.. Immunodiagnosis of opisthorchiasis using parasite cathepsin F. Parasitology research 2015. link 7 Sripa J, Brindley PJ, Sripa B, Loukas A, Kaewkes S, Laha T. Evaluation of liver fluke recombinant cathepsin B-1 protease as a serodiagnostic antigen for human opisthorchiasis. Parasitology international 2012. link 8 Young ND, Campbell BE, Hall RS, Jex AR, Cantacessi C, Laha T et al.. Unlocking the transcriptomes of two carcinogenic parasites, Clonorchis sinensis and Opisthorchis viverrini. PLoS neglected tropical diseases 2010. link 9 Chompo P, Punyapornwithaya V, Sripa B, Tangkawattana S. Leveraging machine learning for predicting Opisthorchis viverrini infection in cats: A tool for veterinary epidemiology. Parasitology international 2026. link 10 Taron W, Jamnongkan W, Kamjanlard C, Phetcharaburanin J, Wangwiwatsin A, Klanrit P et al.. Development of ready-to-use microtiter plates for enhanced ELISA detection of Opisthorchis viverrini antigens in urine samples. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 2025. link 11 Wiraphongthongchai W, Sithithaworn P, Thinkhamrop K, Suwannatrai K, Kopolrat KY, Worasith C et al.. Epidemiology of Strongyloides stercoralis and Opisthorchis viverrini infections in northern and northeastern Thailand: Insights from urine-ELISA surveys. Parasitology research 2024. link 12 Martviset P, Thanongsaksrikul J, Geadkaew-Krenc A, Chaimon S, Glab-Ampai K, Chaibangyang W et al.. Production and immunological characterization of the novel single-chain variable fragment (scFv) antibodies against the epitopes on Opisthorchis viverrini cathepsin F (OvCatF). Acta tropica 2024. link 13 Phupiewkham W, Rodpai R, Inthavongsack S, Laymanivong S, Thanchomnang T, Sadaow L et al.. High prevalence of opisthorchiasis in rural populations from Khammouane Province, central Lao PDR: serological screening using total IgG- and IgG4-based ELISA. Transactions of the Royal Society of Tropical Medicine and Hygiene 2021. link 14 Arimatsu Y, Teimoori S, Surapaitoon A, Sripa B. Production and characterization of monoclonal antibodies against highly immunogenic Opisthorchis viverrini proteins and development of coproantigen detection. Molecular and biochemical parasitology 2020. link 15 Taron W, Jamnongkan W, Techasen A, Phetcharaburanin J, Namwat N, Sithithaworn P et al.. AuNPs-LISA, an efficient detection assay for Opisthorchis viverrini (Ov) antigen in urine. Talanta 2020. link 16 Sudsarn P, Boonmars T, Ruangjirachuporn W, Namwat N, Loilome W, Sriraj P et al.. Combination of Praziquantel and Aspirin Minimizes Liver Pathology of Hamster Opisthorchis viverrini Infection Associated Cholangiocarcinoma. Pathology oncology research : POR 2016. link 17 Duenngai K, Boonmars T, Sithithaworn J, Sithithaworn P. Diagnosis of early infection and post chemotherapeutic treatment by copro-DNA detection in experimental opisthorchiasis. Parasitology research 2013. link 18 Leksomboon R, Chaijaroonkhanarak W, Arunyanart C, Umka J, Jones MK, Sripa B. Organization of the nervous system in Opisthorchis viverrini investigated by histochemical and immunohistochemical study. Parasitology international 2012. link 19 Prakobwong S, Pinlaor P, Charoensuk L, Khoontawad J, Yongvanit P, Hiraku Y et al.. The liver fluke Opisthorchis viverrini expresses nitric oxide synthase but not gelatinases. Parasitology international 2012. link 20 Sri-Aroon P, Intapan PM, Lohachit C, Phongsasakulchoti P, Thanchomnang T, Lulitanond V et al.. Molecular evidence of Opisthorchis viverrini in infected bithyniid snails in the Lao People's Democratic Republic by specific hybridization probe-based real-time fluorescence resonance energy transfer PCR method. Parasitology research 2011. link 21 Tesana S, Srisawangwong T, Sithithaworn P, Itoh M, Phumchaiyothin R. The ELISA-based detection of anti-Opisthorchis viverrini IgG and IgG4 in samples of human urine and serum from an endemic area of north-eastern Thailand. Annals of tropical medicine and parasitology 2007. link 22 Ruangsittichai J, Viyanant V, Vichasri-Grams S, Sobhon P, Tesana S, Upatham ES et al.. Opisthorchis viverrini: identification of a glycine-tyrosine rich eggshell protein and its potential as a diagnostic tool for human opisthorchiasis. International journal for parasitology 2006. link 23 Waikagul J, Dekumyoy P, Chaichana K, Thairungroje Anantapruti M, Komalamisra C, Kitikoon V. Serodiagnosis of human opisthorchiasis using cocktail and electroeluted Bithynia snail antigens. Parasitology international 2002. link00013-2) 24 Wongsaroj T, Sakolvaree Y, Chaicumpa W, Maleewong W, Kitikoon V, Tapchaisri P et al.. Affinity purified oval antigen for diagnosis of Opisthorchiasis viverrini. Asian Pacific journal of allergy and immunology 2001. link 25 Komalamisra C. Chromosomes and C-banding of Opisthorchis viverrini. The Southeast Asian journal of tropical medicine and public health 1999. link 26 Watthanakulpanich D, Waikagul J, Anantaphruti MT, Dekumyoy P. Evaluation of Bithynia funiculata snail antigens by ELISA-serodiagnosis of human opisthorchiasis. The Southeast Asian journal of tropical medicine and public health 1997. link 27 Sakolvaree Y, Ybanez L, Chaicumpa W. Parasites elicited cross-reacting antibodies to Opisthorchis viverrini. Asian Pacific journal of allergy and immunology 1997. link 28 Akai PS, Pungpak S, Chaicumpa W, Kitikoon V, Ruangkunaporn Y, Bunnag D et al.. Serum antibody responses in opisthorchiasis. International journal for parasitology 1995. link00212-7) 29 Sirisinha S, Chawengkirttikul R, Haswell-Elkins MR, Elkins DB, Kaewkes S, Sithithaworn P. Evaluation of a monoclonal antibody-based enzyme linked immunosorbent assay for the diagnosis of Opisthorchis viverrini infection in an endemic area. The American journal of tropical medicine and hygiene 1995. link 30 Akai PS, Pungpak S, Chaicumpa W, Viroj K, Bunnag D, Befus AD. Serum antibody response to Opisthorchis viverrini antigen as a marker for opisthorchiasis-associated cholangiocarcinoma. Transactions of the Royal Society of Tropical Medicine and Hygiene 1994. link90438-3) 31 Akai PS, Pungpak S, Kitikoon V, Bunnag D, Befus AD. Possible protective immunity in human opisthorchiasis. Parasite immunology 1994. link 32 Chaicumpa W, Ybanez L, Kitikoon V, Pungpak S, Ruangkunaporn Y, Chongsa-nguan M et al.. Detection of Opisthorchis viverrini antigens in stools using specific monoclonal antibody. International journal for parasitology 1992. link90155-e) 33 Akai PS, Pungpak S, Kitikoon V, Chaicumpa W, Bunnag D, Befus AD. Separation and characterization of adult worm proteins and glycoproteins from the liver fluke Opisthorchis viverrini. The Journal of parasitology 1992. link 34 Sirisinha S, Chawengkirttikul R, Sermswan R, Amornpant S, Mongkolsuk S, Panyim S. Detection of Opisthorchis viverrini by monoclonal antibody-based ELISA and DNA hybridization. The American journal of tropical medicine and hygiene 1991. link 35 Elkins DB, Sithithaworn P, Haswell-Elkins M, Kaewkes S, Awacharagan P, Wongratanacheewin S. Opisthorchis viverrini: relationships between egg counts, worms recovered and antibody levels within an endemic community in northeast Thailand. Parasitology 1991. link 36 Sirisinha S, Chawengkirttikul R, Sermswan R. Immunodiagnosis of opisthorchiasis. The Southeast Asian journal of tropical medicine and public health 1991. link 37 Ditrich O, Kopacek P, Giboda M, Gutvirth J, Scholz T. Serological differentiation of human small fluke infections using Opisthorchis viverrini and Haplorchis taichui antigens. The Southeast Asian journal of tropical medicine and public health 1991. link 38 Poopyruchpong N, Viyanant V, Upatham ES, Srivatanakul P. Diagnosis of opisthorchiasis by enzyme-linked immunosorbent assay using partially purified antigens. Asian Pacific journal of allergy and immunology 1990. link 39 Sirisinha S, Sahassananda D, Bunnag D, Rim HJ. Immunological analysis of Opisthorchis and Clonorchis antigens. Journal of helminthology 1990. link 40 Srivatanakul P, Viyanant V, Kurathong S, Tiwawech D. Enzyme-linked immunosorbent assay for detection of Opisthorchis viverrini infection. The Southeast Asian journal of tropical medicine and public health 1985. link 41 Feldheim W, Knobloch J. Serodiagnosis of opisthorchis viverrini infestation by an enzyme immuno-assay. Tropenmedizin und Parasitologie 1982. link

Infection by Opisthorchis viverrini